AMG 208 / Amgen - LARVOL DELTA

First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors (ASCO-GU 2013) - P1, N=54; NCT00813384; Sponsor: Amgen; "Of the 42 pts with available tumor response data for site reads, 1 had complete response on bone scan (PC 300 mg) while 2 had partial responses (PR; PC 400 mg and kidney cancer 200 mg; both had -33% tumor shrinkage), and 29 had stable disease (SD); 1 other PC pt had PR after data cutoff. Of the 35 pts with available tumor response data for central reads, 26 had SD."

P1 data • Oncology

The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2/STAT3 cascade. (PubMed, J Exp Clin Cancer Res) - "The HOTAIR/miR-214/ST6GAL1 axis commands the CRC malignancy by modifying c-Met with sialylation and activating JAK2/STAT3 pathway. Our study presents novel insights into CRC progression and provided prospective therapeutic target for CRC."

Journal